Jeito Capital
Paris-based life-sciences venture capital firm founded in 2018 by Rafaele Tordjman, MD PhD, ex-Sofinnova Managing Partner, dedicated to financing breakthrough biopharma innovation for patient benefit across Europe and North America. Two funds: Jeito I closed at EUR 534M in July 2021 and Jeito II at EUR 1.23bn in April 2026, the largest-ever independent biopharma-focused European fund, for around EUR 1.73bn total AUM. The 22-company portfolio counts three trade-sale exits: Neogene Therapeutics to AstraZeneca (USD 320M total, 2023), HI-Bio to Biogen (USD 1.8bn total, July 2024) and EyeBio to Merck (USD 3bn total, late 2024), plus the Nasdaq IPO of Odyssey Therapeutics in May 2026 (ODTX, USD 304M raised).
Key facts
Recent exits
Coverage notes
2 funds tracked, 25 portfolio companies (20 active · 5 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund Jeito Capital has raised, with its portfolio companies. Hand-checked from public filings.
Jeito IIVC2026 · 0yr€1.0B10 active
Unrealized
10 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Biotech |  Denmark | 2026 | |
| Biotech |  US | 2026 | |
| Biotech |  Belgium | 2025 | |
| Biotech | US | 2024 | |
| Biotech |  Netherlands | 2025 | |
| Biotech |  France | 2026 | |
| Biotech | US | 2025 | |
| Biotech | US | 2025 | |
| Biotech |  Switzerland | 2024 | |
| Biotech | US | 2024 |
Denmark· Entry 2026US· Entry 2026Belgium· Entry 2025US· Entry 2024Netherlands· Entry 2025France· Entry 2026US· Entry 2025US· Entry 2025Switzerland· Entry 2024US· Entry 2024Jeito IVC2021 · 5yr€534M10 active · 5 realized
Unrealized
10 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Biotech |  Spain | 2022 | |
| Biotech | Switzerland | 2021 | |
| Biotech |  Germany | 2022 | |
| Biotech | Switzerland | 2022 | |
| Biotech | France | 2023 | |
| Biotech | Denmark | 2022 | |
| Biotech | Switzerland | 2023 | |
| Biotech |  UK | 2021 | |
| Biotech | UK | 2021 | |
| Biotech | France | 2020 |
Spain· Entry 2022Switzerland· Entry 2021Germany· Entry 2022Switzerland· Entry 2022France· Entry 2023Denmark· Entry 2022Switzerland· Entry 2023UK· Entry 2021UK· Entry 2021France· Entry 2020Saved GPs appear in your watchlist, one click from your workspace.
About Jeito Capital
Jeito Capital is a French private equity firm with €534 million of assets under management as of December 2024, headquartered in Paris. Founded in 2018, the firm focuses on buyout and growth equity investments in European mid-cap businesses across healthcare, deploying capital from successive flagship funds with institutional limited partner support.
Investment thesis
Jeito Capital deploys buyout capital into European mid-cap and small-cap businesses across healthcare, targeting majority equity positions in profitable companies with clear value-creation runways. Investment focus emphasises operational improvement, selective bolt-on M&A acceleration and selective international expansion across France and selectively across Europe, with capital deployed from successive flagship funds backed by institutional limited partners.
Recent activity
Realised exits across the current platform vintages remain limited, with the portfolio in active deployment and value-creation phase. The platform tracks 2 fund vehicles, 19 active portfolio companies and 0 realised exits across the strategy's history. Detailed buyer names and multiple data available on Pro at €29/month.
Similar firms
Other private equity firms tracked on GP Intel.
France·€1.6B
France·€1.6B
France·€1.7B
France·€1.5B
France·€1.5B
France·€1.8B
France·€1.3B
France·€2.0B
France·€1.2B
France·€2.0B
France·€2.0B
France·€1.1BGet the full picture on Jeito Capital.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Already a member? Sign in